Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITALIC-RCC: Primary Tumor Ablation in mRCC
NCT06903312Phase 4Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2025
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial, sponsored by Policlinico Gemelli. Primary endpoint: Overall Survival at 30 months. Started Jun 2025; status: recruiting.
Beyond the preview
Go deeper on NCT06903312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06903312.